Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AB Science, Paris (OTC: ABSCF).

Full DD Report for ABSCF

You must become a subscriber to view this report.


Recent News from (OTC: ABSCF)

European advisory group April meeting results
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded its April meeting . More news on: Portola Pharmaceuticals, Radius Health, Inc., AB Science, Paris, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 27 2018 10:34
3 Things In Biotech, April 22: All These 'A' Companies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 23 2018 09:04
3 Things In Biotech You Should Learn Today: September 17, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Pfizer ODAC meeting in earlier stage kidney cancer coming up! At the moment, Pfizer's (PFE)...
Source: SeekingAlpha
Date: September, 17 2017 08:00
Deciphera Pharmaceuticals Seeks $100 Million IPO
Quick Take Waltham, Massachusetts-based Deciphera Pharmaceuticals ( DCPH ), an anti-cancer drug company, intends to raise $100 million in gross proceeds from an IPO of its common stock. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical firm that focuses on kinase inhibi...
Source: SeekingAlpha
Date: September, 07 2017 09:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A4.34N/AN/A0
2018-12-06N/A4.34N/AN/A0
2018-12-05N/A4.34N/AN/A0
2018-12-04N/A4.34N/AN/A0
2018-12-03N/A4.34N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-10-105050100.0000Short
2018-10-085050100.0000Short
2018-09-2550060083.3333Short
2018-06-123843,50010.9714Cover
2018-05-11100100100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABSCF.


About AB Science, Paris (OTC: ABSCF)

Logo for AB Science, Paris (OTC: ABSCF)

AB Science was founded in by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science.

 

Contact Information

 

 

Current Management

  • Alain Moussy / CEO, Founder
    • ngineer ENSTA , and MBA Wharton. Former strategic consultant at Booz, Allen amp Hamilton and former head of Corporate Development at Carrefour. President of AFIRMM, association of mastocytosis patients.

Current Share Structure

  • Market Cap: $379,333,185 - 03/16/2018
  • Issue and Outstanding: 31,349,850 - 07/14/2011

 



Daily Technical Chart for (OTC: ABSCF)

Daily Technical Chart for (OTC: ABSCF)


Stay tuned for daily updates and more on (OTC: ABSCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ABSCF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABSCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABSCF and does not buy, sell, or trade any shares of ABSCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/